Previous 10 | Next 10 |
2023-12-08 12:45:17 ET Gainers: Intensity Therapeutics ( INTS ) +100% . MBIA ( MBI ) +74% . Conduit Pharmaceuticals ( CDT ) +47% . EF Hutton Acquisition Corp I ( EFHT ) +44% . Alx Oncology Holdings ( ALXO ) +35% . View ( VI...
2023-12-08 12:14:56 ET DENVER, Colo., Dec. 8, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; MBIA Inc (NYSE: MBI), Intensity Therapeutics Inc (NASDAQ: INTS), MicroAlgo Inc (NASDAQ: MLGO), ALX Onco...
2023-12-08 10:53:50 ET More on ALX Oncology ALX Oncology: On Right Track With Latest Interim Analysis Of Evorpacept ALX Oncology Holdings: Gilead News Creates A New Risk ALX Oncology GAAP EPS of -$1.24 misses by $0.37 ALX Oncology stock rockets 27% after bein...
2023-12-08 10:06:29 ET DENVER, Colo., Dec. 8, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; MBIA Inc (NYSE: MBI), Intensity Therapeutics Inc (NASDAQ: INTS), Hello Group Inc (NASDAQ: MOMO), MicroAlgo Inc...
2023-12-08 10:00:17 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Bluebird bio, ...
2023-11-21 04:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
ALX Oncology Holdings Inc. (ALXO) is expected to report $-0.86 for Q3 2023
2023-11-14 01:51:28 ET More on ALX Oncology ALX Oncology: On Right Track With Latest Interim Analysis Of Evorpacept ALX Oncology Holdings: Gilead News Creates A New Risk ALX Oncology stock rockets 27% after being halted for volatility ALX Oncology announces p...
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results ...
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that management will participate in three...
News, Short Squeeze, Breakout and More Instantly...
ALX Oncology Holdings Inc. Company Name:
ALXO Stock Symbol:
NASDAQ Market:
ALX Oncology Holdings Inc. Website:
Evorpacept in combination with PADCEV ® , an approved antibody-drug conjugate (“ADC”), demonstrated promising activity and was generally well tolerated Company to host conference call and webcast with Samuel A. Funt, M.D., of Memorial Sloan Kettering Cancer Center on ...
SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that management wi...
2024-05-10 08:30:07 ET H.C. Wainwright analyst issues BUY recommendation for ALXO on May 10, 2024 06:40AM ET. The previous analyst recommendation was Buy. ALXO was trading at $16.95 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...